Bruker: Attractive Valuation Ahead Of An Earnings Inflection

Company Overview - Bruker (BRKR) is positioned for good growth as it enters FY26, benefiting from a healthy backlog and easier year-over-year comparisons [1] - The company is expected to see recovery in key markets, including academic and government sectors, biopharma, and China [1] Financial Insights - Bruker has a backlog of around $40 million, which is anticipated to support its growth trajectory [1]